All patients | Frontline daratumumab patients | Daratumumab initiated in 2 L | Daratumumab initiated in 3 L+ | |
---|---|---|---|---|
N = 299 | N = 26 | N = 66 | N = 207 | |
Best response achieved per IMWG criteria1, n (%) | ||||
Stringent complete response | 16 (5.4) | 5 (19.2) | 6 (9.1) | 5 (2.4) |
Complete response | 25 (8.4) | 4 (15.4) | 4 (6.1) | 17 (8.2) |
Very good partial response | 99 (33.1) | 10 (38.5) | 28 (42.4) | 61 (29.5) |
Partial response | 71 (23.7) | 7 (26.9) | 14 (21.2) | 50 (24.2) |
Minimal response | 4 (1.3) | 0 (0.0) | 2 (3.0) | 2 (1.0) |
Stable disease | 38 (12.7) | 0 (0.0) | 5 (7.6) | 33 (15.9) |
Progressive disease | 43 (14.4) | 0 (0.0) | 7 (10.6) | 36 (17.4) |
Clinical relapse | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Other | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Unknown/not available | 3 (1.0) | 0 (0.0) | 0 (0.0) | 3 (1.4) |
Patients with known response rate, n (%) | 296 (99.0) | 26 (100.0) | 66 (100.0) | 204 (98.6) |
Overall response rate2, n (%) | 211 (71.3) | 26 (100.0) | 52 (78.8) | 133 (65.2) |
Very good partial response or better, n (%) | 140 (47.3) | 19 (73.1) | 38 (57.6) | 83 (40.7) |
Months from regimen start to best response date, mean ± SD [median] | 4.8 ± 5.7 [2.8] | 3.7 ± 3.0 [2.9] | 5.1 ± 4.9 [3.3] | 4.8 ± 6.1 [2.8] |